Statins and the liver.

Abstract

Lipid lowering, particularly with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins"), reduces the risk of cardiovascular disease. Patients with chronic liver disease present challenges to the use of lipid medications. In the case of most liver disorders, the concern has been one of safety. There is evidence that most lipid-lowering medications can be used safely in many situations, although large outcomes trials are lacking. This review examines lipid physiology and cardiovascular risk in specific liver diseases and reviews the evidence for lipid lowering and the use of statins in chronic liver disease.

• Authors: Cynthia Herrick, Samira Bahrainy, Edward A Gill
• Journal: Cardiology clinics (Cardiol Clin) Vol. 33 Issue 2 Pg. 257-65 (May 2015) ISSN: 1558-2264 [Electronic] Netherlands
• PMID: 25939298 (Publication Type: Journal Article, Meta-Analysis, Review)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Lipids
• Transaminases

Topics

• Cardiovascular Diseases (prevention & control)
• Global Health
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects, therapeutic use)
• Incidence
• Lipids (blood)
• Liver (drug effects, metabolism)
• Liver Diseases (blood, epidemiology, etiology)
• Risk Factors
• Transaminases (blood)